Allied Biotech Past Earnings Performance
Past criteria checks 2/6
Allied Biotech has been growing earnings at an average annual rate of 5.6%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 3.7% per year. Allied Biotech's return on equity is 9.1%, and it has net margins of 13.8%.
Key information
5.6%
Earnings growth rate
5.3%
EPS growth rate
Biotechs Industry Growth | 12.2% |
Revenue growth rate | 3.7% |
Return on equity | 9.1% |
Net Margin | 13.8% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Allied Biotech Corporation (GTSM:1780) A Good Dividend Stock?
Apr 16These 4 Measures Indicate That Allied Biotech (GTSM:1780) Is Using Debt Reasonably Well
Mar 05Allied Biotech (GTSM:1780) Has Compensated Shareholders With A Respectable 49% Return On Their Investment
Jan 24Is Allied Biotech Corporation (GTSM:1780) At Risk Of Cutting Its Dividend?
Jan 03A Look At The Intrinsic Value Of Allied Biotech Corporation (GTSM:1780)
Dec 13Is Allied Biotech (GTSM:1780) A Risky Investment?
Nov 25Revenue & Expenses Breakdown
How Allied Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 769 | 106 | 136 | 26 |
31 Mar 24 | 745 | 102 | 134 | 26 |
31 Dec 23 | 720 | 97 | 132 | 26 |
30 Sep 23 | 728 | 121 | 137 | 26 |
30 Jun 23 | 736 | 144 | 142 | 26 |
31 Mar 23 | 727 | 145 | 145 | 25 |
31 Dec 22 | 717 | 147 | 147 | 25 |
30 Sep 22 | 699 | 105 | 139 | 25 |
30 Jun 22 | 681 | 62 | 131 | 25 |
31 Mar 22 | 679 | 38 | 126 | 26 |
31 Dec 21 | 677 | 13 | 121 | 26 |
30 Sep 21 | 658 | 32 | 117 | 25 |
30 Jun 21 | 639 | 51 | 114 | 25 |
31 Mar 21 | 629 | 65 | 114 | 25 |
31 Dec 20 | 618 | 79 | 114 | 25 |
30 Sep 20 | 613 | 72 | 113 | 24 |
30 Jun 20 | 608 | 65 | 112 | 24 |
31 Mar 20 | 624 | 86 | 113 | 24 |
31 Dec 19 | 639 | 107 | 114 | 24 |
30 Sep 19 | 670 | 120 | 120 | 24 |
30 Jun 19 | 700 | 134 | 127 | 24 |
31 Mar 19 | 728 | 138 | 133 | 24 |
31 Dec 18 | 765 | 133 | 131 | 25 |
30 Sep 18 | 764 | 124 | 127 | 27 |
30 Jun 18 | 763 | 114 | 124 | 29 |
31 Mar 18 | 715 | 99 | 115 | 30 |
31 Dec 17 | 682 | 71 | 114 | 28 |
30 Sep 17 | 645 | 53 | 127 | 26 |
30 Jun 17 | 609 | 35 | 139 | 23 |
31 Mar 17 | 603 | 29 | 135 | 23 |
31 Dec 16 | 574 | 40 | 133 | 23 |
30 Sep 16 | 563 | 54 | 120 | 24 |
30 Jun 16 | 552 | 68 | 107 | 25 |
31 Mar 16 | 538 | 57 | 112 | 26 |
31 Dec 15 | 524 | 46 | 116 | 28 |
30 Sep 15 | 516 | 30 | 118 | 28 |
30 Jun 15 | 509 | 13 | 121 | 28 |
31 Mar 15 | 492 | 10 | 122 | 27 |
31 Dec 14 | 474 | 7 | 124 | 26 |
30 Sep 14 | 488 | 11 | 123 | 26 |
30 Jun 14 | 502 | 15 | 121 | 25 |
31 Mar 14 | 491 | 11 | 118 | 25 |
31 Dec 13 | 480 | 6 | 115 | 24 |
Quality Earnings: 1780 has high quality earnings.
Growing Profit Margin: 1780's current net profit margins (13.8%) are lower than last year (19.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1780's earnings have grown by 5.6% per year over the past 5 years.
Accelerating Growth: 1780's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1780 had negative earnings growth (-26.4%) over the past year, making it difficult to compare to the Biotechs industry average (33.2%).
Return on Equity
High ROE: 1780's Return on Equity (9.1%) is considered low.